We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
S&P Futures
5,176.50 +9.00 (+0.17%) Dow Futures
38,297.00 +59.00 (+0.15%) Nasdaq Futures
18,214.75 +35.50 (+0.20%) Russell 2000 Futures
2,028.80 +9.00 (+0.45%) Crude Oil
85.48 -0.18 (-0.21%) Gold
2,372.40 -1.70 (-0.07%)
After hours:
Chart Events
Performance Outlook
| Previous Close | 8.87 |
| Open | 8.43 |
| Bid | 8.11 x 200 |
| Ask | 9.04 x 200 |
| Day's Range | 7.02 - 8.86 |
| 52 Week Range | 7.02 - 42.60 |
| Volume | |
| Avg. Volume | 552,933 |
| Market Cap | 170.71M |
| Beta (5Y Monthly) | 1.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -13.80 |
| Earnings Date | May 07, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AGEN
Related Research
- Agenus Inc.Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.RatingFair ValueEconomic Moat4 days agoMorningstar
- Business Wire
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
LEXINGTON, Mass., April 12, 2024--Agenus Inc. (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced updated results from its Phase 1 clinical trial of BOT/BAL combination therapy in patients with metastatic CRC that is not microsatellite instability-high (MSS) or deficient mismatch repair (dMMR). These findings build upon the compelling clinical activity demonstrated by BOT/BAL across nine different cancer types in Agenus' bro
Motley FoolDown 75%. Is Agenus Stock a Buy on the Dip?
Wall Street analysts who watch the cancer drug developer closely think it could rocket higher.
- Business Wire
Agenus Announces Reverse Stock Split of Common Stock
LEXINGTON, Mass., April 05, 2024--Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced its stockholders have approved a one-for-twenty reverse stock split of its issued and outstanding common stock, which will go into effect at 12:01 a.m., Eastern Time on April 12, 2024. The reverse stock split is intended to give Agenus greater flexibility in its future financing needs and to increase the per share trading price
Motley Fool2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now?
These stocks could rocket higher, but they also present significant risks.
InvestorPlace3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million
Here’s the deal with stocks to turn $1,000 into $1 million: if you want to play, you gotta pay. I’m not just talking about the price of the securities themselves. Indeed, these lesser-known enterprises are relatively low priced. No, the cost comes in the fact that extreme speculation such as this involves an inverse relationship. For maximum potential upside, you typically need to absorb the minimal amount of predictability. Let’s consider blue-chip stocks. Generally, you can be profitable with
Simply Wall St.US$5.50: That's What Analysts Think Agenus Inc. (NASDAQ:AGEN) Is Worth After Its Latest Results
There's been a notable change in appetite for Agenus Inc. ( NASDAQ:AGEN ) shares in the week since its yearly report...
Insider MonkeyAgenus Inc. (NASDAQ:AGEN) Q4 2023 Earnings Call Transcript
Agenus Inc. (NASDAQ:AGEN) Q4 2023 Earnings Call Transcript March 14, 2024 Agenus Inc. misses on earnings expectations. Reported EPS is $-0.13 EPS, expectations were $-0.053. AGEN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. My name is Audra, […]
- Simply Wall St.
Analysts Just Shaved Their Agenus Inc. (NASDAQ:AGEN) Forecasts Dramatically
The latest analyst coverage could presage a bad day for Agenus Inc. ( NASDAQ:AGEN ), with the analysts making...
Motley FoolAgenus (AGEN) Q4 2023 Earnings Call Transcript
AGEN earnings call for the period ending December 31, 2023.
GuruFocus.comAgenus Inc (AGEN) Reports Full Year and Q4 2023 Financial Results, Advances in Oncology Pipeline
Fast Track Designation for BOT/BAL in Colorectal Cancer and $25 Million Milestone Payment Highlight Progress
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| GERN Geron Corporation | |||
| BCRX BioCryst Pharmaceuticals, Inc. | |||
| CRIS Curis, Inc. | |||
| CLDX Celldex Therapeutics, Inc. | |||
| DVAX Dynavax Technologies Corporation |
Similar to AGEN
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| INKT MiNK Therapeutics, Inc. | |||
| IBRX ImmunityBio, Inc. | |||
| VINC Vincerx Pharma, Inc. | |||
| JANX Janux Therapeutics, Inc. | |||
| GERN Geron Corporation |
Analyst Price Targets (4)
Upgrades & Downgrades
| Maintains | B. Riley Securities: Buy to Buy | 3/18/2024 | |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/14/2024 | |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/8/2023 | |
| Reiterates | EF Hutton: Buy to Buy | 7/3/2023 | |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 7/3/2023 | |
| Initiated | Baird: to Outperform | 6/6/2023 |
Company Profile
3 Forbes Road
Lexington, MA 02421-7305
United States
781 674 4400
https://www.agenusbio.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 389
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
